期刊
VIROLOGY
卷 390, 期 2, 页码 298-306出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.virol.2009.05.014
关键词
Vaccinia; NF-kappa B; MVA; Vaccine
类别
资金
- NIH [AI055530]
- NIH Cellular and Molecular Biology Training [T32 GM007283]
Modified vaccinia Ankara (MVA) is an attenuated vaccinia virus, and is a promising vaccine vector for variola and monkeypox viruses, as well as for other pathogens. The MVA determinants important for vaccine efficacy and immunogenicity are poorly defined. MVA infection of fibroblast cells activates NF-kappa B a characteristic not, ascribed to wild-type vaccinia viruses. Thus, NF-kappa B activation, and the subsequent upregulation of host immune molecules, could be one of the determinants for MVA's immunogenicity. We report that ERK2 phosphorylation, an event preceding and required for NF-kappa B activation, occurred rapidly after virus infection. ERK2 and NF-kappa B remained inert when virus endocytosis was prevented, suggesting that virus-host cell interactions were insufficient for activating NF-kappa B. Inhibition of viral protein synthesis decreased NF-kappa B activation, and elimination of intermediate and late gene expression did not alter MVA-induced NF-kappa B ctivation. Thus, early gene expression activates NF-kappa B. (C) 2009 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据